Jump to content

Adenosine A2B receptor

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 01:20, 29 April 2015 (Task 7: replace et al. in author/editor parameters with |display-authors=etal or |display-editors=etal;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Template:PBB The adenosine A2B receptor, also known as ADORA2B, is a G-protein coupled adenosine receptor, and also denotes the human adenosine A2b receptor gene which encodes it.[1]

Template:PBB Summary

Ligands

Research into selective A2B ligands has lagged somewhat behind the development of ligands for the other three adenosine receptor subtypes, but a number of A2B-selective compounds have now been developed,[2][3][4][5][6][7][8][9][10][11] and research into their potential therapeutic applications is ongoing.[12][13][14][15][16][17]

Agonists

  • BAY 60-6583
  • NECA (N-ethylcarboxamidoadenosine)
  • (S)-PHPNECA - high affinity and efficacy at A2B, but poor selectivity over other adenosine receptor subtypes
  • LUF-5835
  • LUF-5845 - partial agonist

Antagonists and inverse agonists

  • Compound 38:[18] antagonist, high affinity and good subtype selectivity
  • ATL-801
  • CVT-6883
  • MRS-1706
  • MRS-1754
  • OSIP-339,391
  • PSB-603
  • PSB-0788
  • PSB-1115

References

  1. ^ "Entrez Gene: ADORA2B adenosine A2b receptor".
  2. ^ Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G (July 2002). "N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands". Journal of Medicinal Chemistry. 45 (15): 3271–9. doi:10.1021/jm0109762. PMID 12109910.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Volpini R, Costanzi S, Lambertucci C, Vittori S, Cristalli G (2002). "Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists". Current Pharmaceutical Design. 8 (26): 2285–98. doi:10.2174/1381612023392856. PMID 12369946.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Baraldi PG, Tabrizi MA, Preti D, Bovero A, Romagnoli R, Fruttarolo F, Zaid NA, Moorman AR, Varani K, Gessi S, Merighi S, Borea PA (March 2004). "Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists". Journal of Medicinal Chemistry. 47 (6): 1434–47. doi:10.1021/jm0309654. PMID 14998332.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Cacciari B, Pastorin G, Bolcato C, Spalluto G, Bacilieri M, Moro S (December 2005). "A2B adenosine receptor antagonists: recent developments". Mini Reviews in Medicinal Chemistry. 5 (12): 1053–60. doi:10.2174/138955705774933374. PMID 16375751.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Baraldi PG, Romagnoli R, Preti D, Fruttarolo F, Carrion MD, Tabrizi MA (2006). "Ligands for A2B adenosine receptor subtype". Current Medicinal Chemistry. 13 (28): 3467–82. doi:10.2174/092986706779010306. PMID 17168717.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Beukers MW, Meurs I, Ijzerman AP (September 2006). "Structure-affinity relationships of adenosine A2B receptor ligands". Medicinal Research Reviews. 26 (5): 667–98. doi:10.1002/med.20069. PMID 16847822.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Elzein E, Kalla R, Li X, Perry T, Parkhill E, Palle V, Varkhedkar V, Gimbel A, Zeng D, Lustig D, Leung K, Zablocki J (January 2006). "Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 16 (2): 302–6. doi:10.1016/j.bmcl.2005.10.002. PMID 16275090.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Carotti A, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Stefanachi A, Vidal B (January 2006). "Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor". Journal of Medicinal Chemistry. 49 (1): 282–99. doi:10.1021/jm0506221. PMID 16392813.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Tabrizi MA, Baraldi PG, Preti D, Romagnoli R, Saponaro G, Baraldi S, Moorman AR, Zaid AN, Varani K, Borea PA (March 2008). "1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists". Bioorganic & Medicinal Chemistry. 16 (5): 2419–30. doi:10.1016/j.bmc.2007.11.058. PMID 18077171.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Stefanachi A, Brea JM, Cadavid MI, Centeno NB, Esteve C, Loza MI, Martinez A, Nieto R, Raviña E, Sanz F, Segarra V, Sotelo E, Vidal B, Carotti A (March 2008). "1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor". Bioorganic & Medicinal Chemistry. 16 (6): 2852–69. doi:10.1016/j.bmc.2008.01.002. PMID 18226909.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003). "Medicinal chemistry and pharmacology of A2B adenosine receptors". Current Topics in Medicinal Chemistry. 3 (4): 427–43. doi:10.2174/1568026033392264. PMID 12570760.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Gao ZG, Jacobson KA (September 2007). "Emerging adenosine receptor agonists". Expert Opinion on Emerging Drugs. 12 (3): 479–92. doi:10.1517/14728214.12.3.479. PMID 17874974.
  14. ^ Kolachala V, Ruble B, Vijay-Kumar M, Wang L, Mwangi S, Figler H, Figler R, Srinivasan S, Gewirtz A, Linden J, Merlin D, Sitaraman S (September 2008). "Blockade of adenosine A2B receptors ameliorates murine colitis". British Journal of Pharmacology. 155 (1): 127–37. doi:10.1038/bjp.2008.227. PMC 2440087. PMID 18536750.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ^ Haskó G, Linden J, Cronstein B, Pacher P (September 2008). "Adenosine receptors: therapeutic aspects for inflammatory and immune diseases". Nature Reviews Drug Discovery. 7 (9): 759–70. doi:10.1038/nrd2638. PMC 2568887. PMID 18758473.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ Ham J, Rees DA (December 2008). "The adenosine a2b receptor: its role in inflammation". Endocrine, Metabolic & Immune Disorders Drug Targets. 8 (4): 244–54. doi:10.2174/187153008786848303. PMID 19075778.
  17. ^ Kim MO, Kim MH, Lee SH, Suh HN, Lee YJ, Lee MY, Han HJ (June 2009). "5'-N-ethylcarboxamide induces IL-6 expression via MAPKs and NF-kappaB activation through Akt, Ca(2+)/PKC, cAMP signaling pathways in mouse embryonic stem cells". Journal of Cellular Physiology. 219 (3): 752–9. doi:10.1002/jcp.21721. PMID 19194991.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  18. ^ Stefanachi A, Nicolotti O, Leonetti F; et al. (2008). "1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A(2B) adenosine receptor antagonists: Design, synthesis, structure-affinity and structure-selectivity relationships". Bioorganic & Medicinal Chemistry. 16 (22): 9780–9. doi:10.1016/j.bmc.2008.09.067. PMID 18938084.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • "Adenosine Receptors: A2B". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.

Further reading

Template:PBB Further reading

Template:PBB Controls

Retrieved from "https://en.wikipedia.org/w/index.php?title=Adenosine_A2B_receptor&oldid=659783919"